Cogent Biosciences, Inc. COGT
32.31
0.88
2.80%
as of 25 Sep
- Market cap
- $5.5B
- P/E
- 0.0×
Follow COGT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 5.37 | 0.98 | 11.25 | 13.52 | 13.52 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | (13.29) | (2.60) | (12.14) | (17.39) | (17.39) |
P/B ratio |
— | — | — | — | — | 1.01 | 0.69 | 1.82 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | 1.01 | 0.69 | 1.82 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | (4.95) | (0.49) | 3.18 | 8.62 | 8.62 |
EV/EBITDA |
— | — | — | — | — | 1.41 | 0.36 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | 3.20 | 0.27 | (0.95) | (2.80) | (2.80) |
EV/FCF |
— | — | — | — | — | 4.21 | 0.27 | (0.94) | (2.70) | (2.70) |
Quick Ratio |
14.08 | 5.15 | 6.96 | 9.70 | 12.86 | 18.50 | 2.98 | 3.22 | 3.74 | 7.95 |
Current Ratio |
14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.79 | 7.98 |
Net Debt/EBITDA |
2.04 | 1.02 | 1.26 | 1.63 | 2.90 | 2.93 | 1.07 | 2.25 | 1.64 | 3.76 |
Debt/Assets |
23.77% | 0.00% | 0.00% | 6.06% | 0.36% | 1.26% | 8.93% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.35 | 0.00 | 0.00 | 0.07 | 0.00 | 0.01 | 0.14 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.33 | 0.14 | 0.13 | 0.17 |
Operating CF/Net income |
0.80 | 0.81 | 0.80 | 0.85 | 0.81 | 0.20 | 1.30 | 0.94 | 1.01 | 1.02 |
Capex/Depreciation |
(1.29) | 0.11 | 0.96 | 8.62 | (11.69) | 11.69 | 0.14 | (0.51) | (0.77) | (3.90) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (94.98%) | (148.99%) | (99.26%) | (88.01%) | (57.23%) | (230.42%) | (69.21%) | (606.74%) | 69.50% | 49.46% | |
| (51.99%) | (79.79%) | (62.65%) | (52.63%) | (29.93%) | (119.34%) | (47.04%) | (51.17%) | (41.00%) | (48.15%) | |
ROIC |
0.00% | 0.00% | 0.00% | (688.01%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(38.61%) | (103.49%) | (79.86%) | (57.03%) | (34.87%) | (77.26%) | (108.99%) | (58.25%) | (72.41%) | (27.74%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | 32.45 | 62.55 | 36.24 | 53.30 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 922.98% | 194.27% | 393.31% | 356.84% | 346.06% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 221.34% | 48.75% | 76.58% | 55.98% | 54.02% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 76.45% | 14.41% | 31.72% | 16.04% | 15.99% |
Graham Net Nets |
— | — | — | — | — | 1.84 | 1.04 | 0.50 | (0.49) | (0.49) |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 65.69 | 0.00 |
Earnings Yield |
— | — | — | — | — | (114.78%) | (307.71%) | (36.36%) | (22.51%) | (22.51%) |
Free Cash Flow Yield |
— | — | — | — | — | (21.87%) | (188.39%) | (30.16%) | (23.61%) | (23.61%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.71 | 2.95 | 1.56 | 3.28 | 2.49 |
Operating CF per Share |
(2.05) | (2.00) | (1.93) | (2.02) | (1.52) | (3.24) | (5.45) | (5.22) | (10.14) | (7.32) |
Capex per Share |
(0.01) | (0.01) | (0.04) | (0.12) | (0.04) | 0.76 | 0.02 | (0.09) | (0.36) | (1.30) |
Free Cash Flow per Share |
(2.06) | (2.01) | (1.96) | (2.14) | (1.56) | (2.48) | (5.43) | (5.31) | (10.50) | (8.62) |
Cash per Share |
6.99 | 2.76 | 3.34 | 4.44 | 5.67 | 21.86 | 4.91 | 12.63 | 16.11 | 26.89 |
Shareholders Equity per Share |
4.94 | 2.47 | 3.24 | 4.35 | 5.53 | 21.18 | 4.17 | 9.68 | (19.17) | (9.69) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.94 | 2.47 | 3.24 | 4.35 | 5.53 | 21.18 | 4.17 | 9.68 | (19.17) | (9.69) |
Free Cash Flow |
(266.00) | (208.36) | (156.42) | (125.50) | (60.48) | (27.43) | (41.34) | (33.04) | (26.75) | (21.95) |
Working Capital |
846.40 | 240.76 | 232.60 | 238.12 | 205.56 | 231.82 | 27.34 | 56.06 | 31.19 | 61.00 |
Capital Expenditures |
(1.55) | (0.57) | (2.80) | (6.86) | (1.72) | 8.42 | 0.17 | (0.55) | (0.91) | (3.31) |
Net Current Asset Value |
609.12 | 224.86 | 215.14 | 219.89 | 204.73 | 228.66 | 22.93 | 55.31 | (55.58) | (30.52) |
EV/EBIT |
— | — | — | — | — | 1.39 | 0.34 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.07) | (0.01) | 0.06 | 0.11 | 0.52 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,276.81%) | (141.49%) | (354.92%) | (305.71%) | (286.20%) |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.22 | (0.80) | (0.35) | (0.10) | 0.09 | 5.37 | 0.66 | 0.33 | 0.29 | 0.19 |
Cash ROIC |
(15.34%) | (39.43%) | (30.94%) | (23.65%) | (13.91%) | (7.50%) | (58.94%) | (25.74%) | 383.39% | (52.96%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | 12.27 | 7.79 | 9.51 | 7.23 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
— | — | — | — | — | — | 1.83 | 1.25 | 0.88 | 0.88 |
Average Payables |
10.76 | 11.33 | 8.25 | 4.66 | 2.11 | 1.96 | 2.35 | 1.43 | 1.40 | 1.40 |
Average Assets |
632.75 | 320.67 | 307.12 | 266.45 | 241.50 | 150.17 | 67.68 | 67.52 | 62.33 | 37.78 |
Average Common Equity |
346.33 | 171.73 | 193.84 | 159.34 | 126.29 | 77.77 | 46.00 | 5.69 | (36.77) | (36.77) |
Columns are period end dates